Amgen 2009 Annual Report Download - page 52

years at Baxter Healthcare Corporation in roles of increasing responsibility in law, including Vice President,
Law, for Baxter’s BioScience Division. Also, for more than five years, Ms. Richo served on the Board of Direc-
tors of Cytyc Corporation and was a member of the Audit and Finance Committees.
Mr. David J. Scott, age 57, became Senior Vice President, General Counsel and Secretary in March 2004.
From May 1999 to February 2004, Mr. Scott served as Senior Vice President and General Counsel of Medtronic,
Inc. and also as Secretary from January 2000. From December 1997 to April 1999, Mr. Scott served as General
Counsel of London-based United Distillers & Vintners. Mr. Scott also served in executive roles at Grand Metro-
politan plc and RJR Nabisco, Inc., and was an attorney in private practice.
Geographic Area Financial Information
For financial information concerning the geographic areas in which we operate, see Note 21, “Segment in-
formation — Geographic information” to the Consolidated Financial Statements.
Investor Information
Financial and other information about us is available on our website (http://www.amgen.com) (This website
address is not intended to function as a hyperlink, and the information contained in our website is not intended to
be a part of this filing). We make available on our website, free of charge, copies of our annual report on Form
10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or
furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing or
submitting such material electronically or otherwise furnishing it to the SEC. In addition, we have previously
filed registration statements and other documents with the SEC. Any document we file may be inspected, without
charge, at the SEC’s public reference room at 100 F Street NE, Washington, D.C. 20549 or at the SEC’s internet
address at http://www.sec.gov. Information related to the operation of the SEC’s public reference room may be
obtained by calling the SEC at 1-800-SEC-0330.
Item 1A. RISK FACTORS
This report and other documents we file with the SEC contain forward looking statements that are based on
current expectations, estimates, forecasts and projections about us, our future performance, our business or others
on our behalf, our beliefs and our management’s assumptions. These statements are not guarantees of future per-
formance and involve certain risks, uncertainties and assumptions that are difficult to predict. You should
carefully consider the risks and uncertainties facing our business. The risks described below are not the only ones
facing us. Our business is also subject to the risks that affect many other companies, such as employment rela-
tions, general economic conditions, geopolitical events and international operations. Further, additional risks not
currently known to us or that we currently believe are immaterial also may impair our business, operations,
liquidity and stock price materially and adversely.
Our current products and products in development cannot be sold if we do not gain or maintain regulatory
approval.
Our business is subject to extensive regulation by numerous state and federal governmental authorities in
the United States, including the FDA, and by foreign regulatory authorities, including the EMA. We are required
in the United States and in foreign countries to obtain approval from regulatory authorities before we can manu-
facture, market and sell our products. Once approved, the FDA and other U.S. and foreign regulatory agencies
have substantial authority to require additional testing, change product labeling or mandate withdrawals of our
products. Also, regulatory agencies could add new regulations or change existing regulations at any time, which
could affect our ability to obtain or maintain approval of our products. Regulatory reform efforts currently under
discussion by U.S. policymakers may include changes to applicable laws and regulations that could have a sig-
nificant impact on our business. For example, the 2007 creation of the FDAAA significantly added to the FDA’s
authority, allowing the FDA to (i) require sponsors of marketed products to conduct post-approval clinical stud-
40